On January 12, 2017, CMS initiated coverage for use of CGM among insulin-treated diabetes beneficiaries who met the following eligibility criteria: (1) diagnosis of diabetes; (2) documentation of frequent SMBG (defined as testing ≥4 times daily); (3) treatment with intensive insulin therapy (defined as ≥3 insulin injections per day or use of a Medicare-covered insulin pump); (4) frequent adjustment of insulin dosages based on blood glucose measurements; (5) face-to-face consultation with clinician before initiating CGM; and (6) follow-up face-to-face clinical consultations every 6 months. This evidence concerns the gene INS and diabetes mellitus.